Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort

Abstract Objectives to evaluate over a 48-month follow-up period the: 1) long-term effectiveness and safety; 2) drug retention rate (DRR); 3) impact of comorbidities and bDMARDs line on MDA and DAPSA remission/low disease activity (LDA) of secukinumab in a multicenter Italian cohort of PsA patients....

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Roberta Ramonda, Mariagrazia Lorenzin, Maria Sole Chimenti, Fabiola Atzeni, Angelo Semeraro, Salvatore D’Angelo, Carlo Selmi, Augusta Ortolan, Antonio Marchesoni, Maria Manara, Michele Maria Luchetti Gentiloni, Leonardo Santo, Carlo Salvarani, Alberto Cauli, Maurizio Rossini, Giorgio Amato, Giacomo Cozzi, Laura Scagnellato, Mario Ferraioli, Antonio Carriero, Elena Fracassi, Francesco Giorgio, Andrea Doria, Rosario Foti, Antonio Carletto, on behalf Spondyloarthritis and Psoriatic Arthritis SIR Study Group “Antonio Spadaro”
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMC 2024-09-01
Saila:	Arthritis Research & Therapy
Gaiak:	Psoriatic arthritis Biologics Secukinumab Remission/Effectiveness Safety Drug retention rate
Sarrera elektronikoa:	https://doi.org/10.1186/s13075-024-03401-x
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!